[1] |
YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao.
A National Pharmacovigilance Management System in a New Era
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281.
|
[2] |
SUN Ximu, ZHOU Han, LI Yanming, GUO Peng, NIE Xiaolu.
Signal Mining and Analysis of ICIs-Associated Thrombocytopenia Adverse Events Based on FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 23-28.
|
[3] |
LIN Lu, ZHAN Luchuan, LIU Xiaoqi, LIU Ju'e, WANG Laiyou, ZENG Ying, LAI Weihua.
Establish triggers for active monitoring of digoxin adverse events based on the China hospital pharmacovigilance system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1039-1043.
|
[4] |
SUN Yixin, NIE Xiaolu, WANG Xiaoling, GUO Peng.
Comparative research on active post-marketing drug safety surveillance systems worldwide based on real-world data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 892-899.
|
[5] |
WEI Fenfang, WU Wenyu, LI Limin, TANG Biyu, WU Jianru.
Foreign methods for benefit-risk assessment of pharmaceutical products
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 900-905.
|
[6] |
WANG Dan, DONG Duo, TIAN Chunhua.
Course of development of pharmocovigilance systems in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 735-740.
|
[7] |
SHAO Bo, GUO Xiaoxin.
Review of pharmacovigilance of traditional Chinese medicine
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 741-745.
|
[8] |
ALATENG Hua, WANG Zhenxing, ZHANG Xiaomeng, SHI Wei, XI Chengwei, WANG Conghui, WANG Liqun, ZHANG Bing.
Mining and analysis of cardiac disorders risk signals based on adverse drug reaction monitoring data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 752-758.
|
[9] |
LIU Yadi, ZHANG Xiaomeng, CAI Haili, CHEN Siying, WANG Yu, ZHANG Bing.
Traditional Chinese medicine for prevention and treatment of adriamycin cardiotoxicity and an empirical study of evidence elements
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 759-764.
|
[10] |
CAI Haili, ZHANG Xiaomeng, LIU Yadi, LIU Shujia, GAO Fujun, WANG Yu, ZHANG Bing.
Progress in construction and evaluation of a drug-induced cardiotoxicity model
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 765-770.
|
[11] |
ALATENG Hua, GAO Lei, ZHANG Xiaomeng, ZHANG Bing.
Exploring the scientific connotation of Mongolian Medicine pharmacovigilance based on ancient Mongolian Medical literature
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 677-682.
|
[12] |
WANG Chunnan, QIN Shiru, ZHANG Meng, SONG Haibo, LIU Junchang, LI Ge, SUN Feng.
Evaluation of drug safety with multicenter real-world data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 703-708.
|
[13] |
LI haiyan, YANG Zhongxu, LIU Yuekun, WANG Lihong.
Pharmaceutical care of serious adverse reactions due to methotrexate treatment of ectopic pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 454-456.
|
[14] |
WANG Dandan, WANG Ying, YAO Lingwen, LIU Yuanxi, JIN Hongyu, MA Shuangcheng.
Determination of residual solvents in extract of Coleus amboinicus by headspace-gas chromatography
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 295-299.
|
[15] |
MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin.
Drug traceability coding system in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
|